Pharma Stock

Jump to

Zydus Life stock drops 6% after acquisition of 50% stake in Sterling Biotech; Citi maintains 'Sell'

The analysts at the brokerage house Citi have maintained a sell rating on the counter of Zydus Life, recommending a share price target of Rs 890 per share from its current levels.
Cipla Q3 profit up 10%, brokerages remain positive

Macquarie has kept ‘Outperform’ rating on Cipla with a target at Rs 1,235 per share
Dr Reddy's Lab top pick in pharma: IIFL Capital

Bino Pathiparampil of IIFL Capital told CNBC-TV18 that there has been a major rally in the sector over the last couple of years. Thus, many of the stocks went up 20 percent in the last couple of months itself.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Pharma Stock

Zydus Life stock drops 6% after acquisition of 50% stake in Sterling Biotech; Citi maintains 'Sell'

Cipla Q3 profit up 10%, brokerages remain positive

Dr Reddy's Lab top pick in pharma: IIFL Capital